Stage 3 bladder cancer means the tumor has grown through the full thickness of the bladder wall and into the surrounding fatty tissue or nearby organs. It has not spread to distant parts of the body, which separates it from stage 4, but it may involve nearby lymph nodes. The five-year relative survival rate for this regional stage of bladder cancer is 39%, though individual outcomes vary widely based on treatment response, overall health, and how far into the surrounding tissue the cancer has reached.
How Stage 3 Differs From Earlier Stages
In stage 2 bladder cancer, the tumor has invaded the thick muscle wall of the bladder but remains contained within it. Stage 3 is defined by the cancer breaking through that muscle wall entirely. Once it does, it can reach the soft fatty tissue that surrounds the bladder (called perivesical tissue) or grow directly into adjacent organs like the prostate or seminal vesicles in men, or the uterus or vagina in women.
This distinction matters because a tumor confined to the bladder muscle is easier to remove cleanly with surgery. Once cancer pushes through the wall, treatment becomes more complex and typically involves a combination of chemotherapy and surgery rather than surgery alone.
Stage 3A vs. Stage 3B
Stage 3 is split into two substages, and the difference comes down to lymph node involvement. In stage 3A, the cancer has grown through the bladder wall into surrounding fat or nearby reproductive organs, but either no lymph nodes are affected or the cancer has reached only a single pelvic lymph node that sits away from the major arteries in the pelvis (the common iliac arteries).
Stage 3B means cancer has spread to two or more pelvic lymph nodes, or to at least one lymph node located near those common iliac arteries. More lymph node involvement generally signals a higher risk that cancer cells have traveled further, which affects both treatment planning and prognosis. Stage 3B is considered more advanced, and treatment plans often reflect that increased complexity.
Symptoms at This Stage
Many people with bladder cancer first notice blood in their urine or changes in urinary habits at earlier stages. By stage 3, additional symptoms can develop as the tumor presses on or invades surrounding structures. These include difficulty urinating or a complete inability to urinate, lower back pain, appetite loss, unexplained weight loss, fatigue, and swelling in the feet. Some people also experience bone pain, though this is more common when cancer has spread further. Not everyone will have all of these symptoms, and some people with stage 3 disease feel relatively well.
How Stage 3 Is Diagnosed
Staging relies heavily on imaging. CT scans, specifically a version called CT urography, are the most commonly used tool worldwide for diagnosing and staging bladder cancer. CT is particularly good at detecting whether cancer has spread to lymph nodes or distant organs.
MRI provides better soft-tissue detail than CT, making it more accurate for determining how deeply the tumor has invaded locally. A multiparametric MRI combines structural images with functional scans that show how water molecules move through tissue and how blood flows through the tumor. This gives doctors a more detailed picture of whether cancer has broken through the bladder wall. PET scans, which highlight areas of high metabolic activity, are used when doctors suspect the cancer may have spread beyond the pelvis or need to monitor how treatment is working.
Most patients also undergo a procedure where a scope is passed through the urethra to directly examine the bladder and take tissue samples. These biopsies confirm the cancer type and grade under a microscope.
Primary Treatment: Surgery and Chemotherapy
The standard treatment for stage 3 bladder cancer is radical cystectomy, which means removing the entire bladder along with surrounding tissues. In men, this typically includes the prostate and seminal vesicles. In women, it may include the uterus, ovaries, and part of the vagina. Nearby lymph nodes are also removed to check for cancer spread.
Chemotherapy given before surgery has been shown to help people live longer than surgery alone. This pre-surgical chemotherapy, which includes a platinum-based drug, aims to shrink the tumor and eliminate microscopic cancer cells that may have escaped the bladder before the surgeon operates. Patients who are healthy enough to tolerate this combination typically receive several cycles of chemotherapy over a few months before their surgery date.
For people who cannot have surgery or choose not to, the main alternative is radiation therapy combined with chemotherapy given at the same time. The chemotherapy makes the radiation more effective against the tumor. This bladder-preserving approach can be a reasonable option, though it requires close monitoring afterward to catch any recurrence early.
Life After Bladder Removal
Once the bladder is removed, the body needs a new pathway for urine. There are three main options, and the choice depends on the extent of surgery, the patient’s anatomy, and personal preference.
- Ileal conduit: The most common option. A short segment of small intestine is fashioned into a tube. One end connects to the tubes that carry urine from the kidneys, and the other end exits through a small opening in the abdomen called a stoma. Urine drains continuously into an external collection pouch that sticks to the skin around the stoma.
- Neobladder: A surgeon creates a new bladder-shaped reservoir from a piece of small intestine and connects it to the urethra, so urine exits the body the natural way. There is no external bag. However, the neobladder lacks the muscle of a real bladder. Patients initially need to empty it every one to three hours, and over time, with pelvic floor training, most gain better control.
- Continent cutaneous pouch: An internal reservoir is made from part of the large intestine, with a one-way valve that prevents leaking. A small stoma on the abdomen allows the patient to insert a thin tube several times a day to drain the pouch. No external bag is worn between catheterizations.
Each option involves a significant adjustment period. Recovery from the cystectomy itself typically takes six to eight weeks, and adapting to the new urinary system takes longer. Patients work closely with specialized nurses who help with stoma care or neobladder training.
Immunotherapy Options
Immunotherapy drugs that help the immune system recognize and attack cancer cells have become an important part of bladder cancer treatment. These drugs work by blocking a protein interaction that cancer cells exploit to hide from immune defenses.
For patients who cannot tolerate platinum-based chemotherapy, checkpoint inhibitor drugs can serve as an alternative treatment. After surgery, one of these immunotherapy drugs has been approved specifically as follow-up therapy for people with high-risk muscle-invasive bladder cancer whose tumors have been removed. The goal is to reduce the chance of recurrence. Clinical trials are also testing the combination of immunotherapy with standard chemotherapy both before and after surgery, with early results showing promise for improved outcomes.
Response rates to immunotherapy vary. In clinical trials, roughly 25 to 38 percent of patients with advanced bladder cancer responded to certain checkpoint inhibitors. That means immunotherapy does not work for everyone, but for those who do respond, the benefits can be durable.
Factors That Influence Outlook
The 39% five-year survival rate for regional bladder cancer is an average across a wide range of situations. Several factors push individual outcomes higher or lower. Whether the cancer has reached lymph nodes matters significantly: stage 3A without lymph node involvement carries a better prognosis than stage 3B with multiple affected nodes. How well the cancer responds to pre-surgical chemotherapy is another strong predictor. Patients whose tumors shrink substantially, or disappear entirely on pathology after surgery, tend to do considerably better.
Age, overall kidney function, and whether someone is healthy enough for the full course of chemotherapy and surgery all play a role. The specific type of bladder cancer cells also matters, as some subtypes are more aggressive than others. Survival statistics are also based on data collected over previous years, so they may not fully reflect improvements from newer immunotherapy combinations now entering routine use.